7月9日，乐心医疗今日收盘15.85元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到48.79倍，创65天以来新低，总市值34.47亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.36倍，行业中值37.22倍，乐心医疗排 名第87位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐心医疗48.7956.173.3834.47亿行业平均 51.3648.894.49106.66亿行业中值37.2238.152.4951.36亿1九安医疗10.2510.370.81173.02亿2英科医疗 10.9511.800.97172.95亿3新华医疗14.3013.251.1791.67亿4奥美医疗15.3515.051.5855.47亿5振德医疗 15.3814.490.9855.82亿6山东药玻15.5415.591.79146.99亿7康德莱15.8115.821.3134.07亿8奥泰生物 16.4317.331.3352.40亿9维力医疗16.5717.221.9437.78亿10九强生物16.5815.422.0382.13亿11安杰思 17. ...

广东乐心医疗电子股份有限公司的主营业务是健康IoT业务以及数字健康服务。公司的主要产品是智能 电子血压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备、智能手环、智能手表。作 为国家级高新技术企业，拥有广东省工程技术研究中心、市级企业技术中心和中山市工程技术研究开发 中心，多年来致力于家用医疗健康电子产品的研发、生产和销售。公司已经通过ISO13485:2016医疗器 械质量体系认证和ISO9001:2015质量管理体系认证及ISO14001:2015环境管理体系。公司出口产品获得 了美国FDA注册认证、欧盟CE认证、日本《指定外国制造事业者指定书》、韩国GMP认证。公司长期 与国外优质高端品牌企业合作，产品出口至欧美、亚洲等多个国家，公司的质量控制体系及产品质量已 达到国际先进水平。 6月18日，乐心医疗今日收盘14.19元，下跌1.60%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到43.68倍，总市值30.86亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，乐心医疗排 名第87位。 资金流向方面，6月18日，乐心医疗主力资金净流 ...

长沙晚报全媒体记者 张洋子 "我们在非洲大有可为。"三诺生物国际销售副总监胡晓介绍，如今三诺公司系列血糖监测产品以过硬的 产品质量和可负担的价格"圈粉"非洲友人，产品和服务已覆盖埃及、尼日利亚、肯尼亚、坦桑尼亚等40 多个非洲国家，在非销售额预计2026年达到1.6亿元。三诺还计划通过"离线存储+定时上传"技术破解非 洲网络难题，在当地合资建厂，实现"非洲制造"。 越来越多长沙企业，以"产品力" 叩开非洲医药市场大门：在长沙培育的上市企业圣湘生物，合作身影 遍及加纳、加蓬等非洲近50个国家和地区，其产品深度嵌入当地公共卫生体系；三诺生物血糖仪误差率 低于国际标准，阿尔及利亚卫生部的检测报告成为"通行证"；安邦制药的银黄清肺胶囊作为湖南首个在 非注册中成药，在津巴布韦上市即获认可；万脉医疗的呼吸机针对非洲气候改良散热设计，成为南非急 诊室的标配。 在长沙高新区的三诺生物生产车间，机械臂正以每月4万台的速度分装血糖仪，这些印 有"SINOCARE"标识的白色设备，正穿越万里奔赴非洲40余国。 从1973年湖南首支援非医疗队踏上塞拉利昂的土地，到如今长沙医药生产基地陆续在非洲拔地而起，半 个世纪的时光里，长沙对非医 ...

5月27日，乐心医疗今日收盘13.8元，下跌1.36%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到42.48倍，总市值30.01亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.11倍，行业中值35.89倍，乐心医疗排 名第86位。 资金流向方面，5月27日，乐心医疗主力资金净流出454.10万元，近5日总体呈流出状态，5日共流出 2226.31万元。 广东乐心医疗电子股份有限公司的主营业务是健康IoT业务以及数字健康服务。公司的主要产品是智能 电子血压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备、智能手环、智能手表。作 为国家级高新技术企业，拥有广东省工程技术研究中心、市级企业技术中心和中山市工程技术研究开发 中心，多年来致力于家用医疗健康电子产品的研发、生产和销售。公司已经通过ISO13485:2016医疗器 械质量体系认证和ISO9001:2015质量管理体系认证及ISO14001:2015环境管理体系。公司出口产品获得 了美国FDA注册认证、欧盟CE认证、日本《指定外国制造事业者指定书》、韩国GMP认证。公司长期 与国外优质高端品牌企业合作，产品出口至 ...

最新一期业绩显示，2025年一季报，公司实现营业收入2.73亿元，同比9.90%；净利润2294.20万元，同 比67.88%，销售毛利率37.38%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)86乐心医疗44.5151.243.0831.45亿行业平均 48.9847.404.56104.17亿行业中值36.1637.662.3446.18亿1天益医疗-1712.92-2934.031.8321.83亿2澳华内 镜-592.52297.184.7562.44亿3诺唯赞-411.67-486.902.2688.10亿4爱朋医疗-344.10261.424.1528.23亿5博晖 创新-324.60515.093.4647.63亿6硕世生物-125.58-1835.121.1336.73亿7奥精医疗-121.29-177.781.6022.51亿 8睿昂基因-99.04-81.321.4012.82亿9康泰医学-82.90-70.042.9654.56亿10中红医疗-68.19-54.390.8647.39亿 11华大智造-60.09-53.324.14320.38亿 来源：金融界 5月9日，乐心 ...

Core Viewpoint - The company emphasizes its commitment to innovation and sustainable growth in the diabetes management sector, despite recent stock price fluctuations and market challenges [1][4][5]. Financial Performance - In 2024, the company achieved a revenue of 4.44 billion yuan, a year-on-year increase of 9.47%, and a net profit attributable to shareholders of 326.29 million yuan, up 14.73% [1]. - In Q1 2025, the company reported a revenue of 1.04 billion yuan, a 2.76% increase year-on-year, but a net profit of 72.12 million yuan, down 10.90% compared to the previous year [1][8]. Industry Outlook - The global adult diabetes patient population is projected to reach 853 million by 2050, with China accounting for approximately 148 million patients in 2024, representing 25% of the global total [1]. - The demand for blood glucose monitoring products is expected to rise significantly due to the aging population and increasing health management awareness in developing countries [1][2]. Product Development and Strategy - The company is focused on building a comprehensive diabetes management ecosystem through innovative products like Continuous Glucose Monitoring (CGM) systems and partnerships with healthcare institutions [2][3]. - The CGM product line is a strategic focus for the company, with expected revenues of 200-300 million yuan in 2024 [3][4]. Market Position and Competition - The domestic CGM market is experiencing rapid growth, with the company actively expanding its market share and optimizing its product offerings [6][7]. - The company is committed to maintaining its leadership position in the diabetes monitoring sector through continuous innovation and service enhancement [6][7]. Shareholder Engagement - The company has implemented multiple share repurchase plans to enhance shareholder value and market confidence, with a total repurchase amounting to approximately 64.1 million yuan as of April 30, 2025 [1][4][5]. - The management acknowledges the importance of investor communication and aims to improve transparency and information disclosure [1][4].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's 2024 revenue reached 4.443 billion yuan, a year-on-year increase of 9.47%, with a net profit attributable to shareholders of 326 million yuan, up 14.73% year-on-year [1] - The sales of Continuous Glucose Monitoring (CGM) products are expected to accelerate, with projected sales of approximately 300 million yuan in 2024 [2][3] - The company has established a global sales network and is expected to see improvements in its overseas subsidiaries, indicating potential for international expansion [3] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 4.443 billion yuan, with a net profit of 326 million yuan and a non-recurring net profit of 295 million yuan [1] - The Q4 revenue was 1.261 billion yuan, showing a year-on-year growth of 23.22%, while Q1 2025 revenue was 1.042 billion yuan, a year-on-year increase of 2.76% [1][2] Business Segments - Blood Glucose Monitoring (BGM) revenue for 2024 was 3.321 billion yuan, reflecting a year-on-year growth of 15.58% [2] - The company anticipates steady growth in its BGM business for 2025, supported by a robust product system and distribution network [2] CGM Product Development - The company is a leading player in the domestic CGM market, with its products launched in 2023 and expected to see significant sales growth [2] - The second-generation CGM products are anticipated to be launched soon, further enhancing the product lineup [2] International Expansion - The company has received CE certification for its CGM products and is in the process of entering markets in Western and Northern Europe [3] - An FDA application for the CGM products has been submitted, with expectations for approval in 2025 [3] Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2025 is set at 431 million yuan, with a downward adjustment for 2026 to 523 million yuan [3] - The company is recognized as the leading brand in domestic blood glucose monitoring, with promising prospects for international business [3]

4月29日，乐心医疗今日收盘14.21元，上涨3.50%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到43.75倍，创18天以来新低，总市值30.90亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均47.74倍，行业中值36.15倍，乐心医疗排 名第84位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)84乐心医疗43.7550.363.0330.90亿行业平均 47.7444.884.40101.07亿行业中值36.1535.662.2846.25亿1硕世生物-1832.01-1832.011.1236.67亿2天益医 疗-1617.63-2770.811.7320.61亿3澳华内镜-556.10278.924.4658.61亿4诺唯赞-416.32-492.392.2889.09亿5博 晖创新-319.59507.143.4146.89亿6爱朋医疗-296.17225.003.5724.30亿7奥精医疗-114.89-168.391.5221.32亿 8睿昂基因-90.84-74.581.2911.76亿9康泰医学-80.95-68.392.8953.28亿10中红 ...

业绩简述 2025 年 4 月 28 日，公司发布 2025 年一季度报告，25Q1 公司实现 收入 10.42 亿元，同比+2.76%；归母净利润 7212 万元，同比- 10.90%；扣非归母净利润 6684 万元，同比-13.84%。 经营分析 一季度销售费用投入增加，CGM 产品有望快速放量。一季度公司收 入端保持稳健增长，以血糖监测产品为核心的慢性病快速检测业 务经营平稳。Q1 公司销售费用投入 2.89 亿元，同比+19.57%，预 计针对新产品 CGM 的国内外推广投入仍在持续，短期利润端增速 有一定压力，但 CGM 产品保持快速增长趋势，份额有望持续提升。 重视创新研发投入，第二代 CGM 产品顺利获批。2024 年 12 月公司 公告新一代 CGM 产品国内获批，CGM 二代新产品在设计、工艺上进 一步改进。相较于一代产品，公司持续葡萄糖监测系统二代产品采 用一体式植入，无需组装，用户佩戴更简单；此外公司进一步优化 了产品尺寸，能够带给用户更好的佩戴体验。 签订欧洲 CGM 合作协议，海外市场有望逐步放量。2024 年 12 月公 司披露了关于签订日常经营重要合同的公告，公司与 A. MEN ...